European Neuropsychopharmacology最新文献

{"title":"Retinal structure and its relationship with premorbid, clinical, and cognitive variables in young Spanish patients with early course schizophrenia spectrum disorders.","authors":"Jairo M González-Díaz, Bernardo Sánchez Dalmau, Anna Camós-Carreras, Salut Alba-Arbalat, Silvia Amoretti, Maria Florencia Forte, Maria Serra-Navarro, Sergi Salmerón, Anaid Pérez-Ramos, Eduard Vieta, Carla Torrent, Miquel Bernardo","doi":"10.1016/j.euroneuro.2024.12.006","DOIUrl":"https://doi.org/10.1016/j.euroneuro.2024.12.006","url":null,"abstract":"<p><p>Emerging evidence suggests that retinal structural alterations are present in schizophrenia spectrum disorders (SSD), potentially reflecting broader neurodevelopmental and neurodegenerative processes. This cross-sectional study investigates retinal thickness and its clinical correlations in a sample of early-course SSD patients compared to healthy controls (HCs). One hundred-two eyes from 26 SSD cases and 25 age- and sex-matched HCs were included. Retinal structure was evaluated using Spectral-Domain Optical Coherence Tomography (SD-OCT), focusing on the peripapillary retinal nerve fiber layer (pRNFL), macular volume/thickness, and ganglion cell-inner plexiform layer (GCL+IPL) thickness. Although SSD cases showed increased peripapillary retinal nerve fiber layer (pRNFL) thickness in specific quadrants, most retinal parameters did not differ significantly between groups. Preliminary associations were observed between retinal measures, premorbid adjustment, DUP, and cognitive performance. These findings, while suggesting the potential of retinal imaging as a tool for early detection and monitoring of psychotic disorders, must be interpreted with caution. Further longitudinal and multimodal research is warranted to explore the association between these retinal changes and neuroinflammation, neurodegeneration, and overall brain health in SSD patients.</p>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"92 ","pages":"38-47"},"PeriodicalIF":6.1,"publicationDate":"2024-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142881537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting the past: The risks and rewards of post-hoc findings.","authors":"Vincenzo Oliva, Eduard Vieta","doi":"10.1016/j.euroneuro.2024.12.005","DOIUrl":"https://doi.org/10.1016/j.euroneuro.2024.12.005","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"92 ","pages":"21-22"},"PeriodicalIF":6.1,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142876652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redefining schizophrenia treatment with muscarinic modulation-A perspective.","authors":"Muhammad Furqan","doi":"10.1016/j.euroneuro.2024.11.014","DOIUrl":"https://doi.org/10.1016/j.euroneuro.2024.11.014","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"92 ","pages":"19-20"},"PeriodicalIF":6.1,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Examining the impact of comorbid posttraumatic stress disorder on ketamine's real-world effectiveness in treatment-resistant depression.","authors":"Danica E Johnson, Nelson B Rodrigues, Sydney Weisz, Noah Chisamore, Erica S Kaczmarek, David C J Chen-Li, Zoe Doyle, J Don Richardson, Rodrigo B Mansur, Roger S McIntyre, Joshua D Rosenblat","doi":"10.1016/j.euroneuro.2024.11.008","DOIUrl":"https://doi.org/10.1016/j.euroneuro.2024.11.008","url":null,"abstract":"<p><p>Depression with comorbid posttraumatic stress disorder (PTSD) is associated with more severe symptoms and a reduced response to traditional treatments. Although ketamine shows promise as a rapid-acting antidepressant for treatment-resistant depression (TRD), its effectiveness in patients with comorbid PTSD remains underexplored. Therefore, we conducted a retrospective analysis of 134 patients from the Canadian Rapid Treatment Center of Excellence to compare the effectiveness of four ketamine infusions (0.5-0.75 mg/kg) in reducing symptoms of depression and PTSD in TRD patients with and without comorbid PTSD. A repeated-measures linear mixed model was used to evaluate the impact of comorbid PTSD on ketamine's antidepressant effectiveness, measured by the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR16). Paired samples t-tests were used to assess changes in PTSD symptoms, measured by the PTSD Checklist for DSM-5 (PCL-5). We found a significant main effect of time on QIDS-SR16 scores, F(4, 209.32) = 36.67, p < 0.001, but no significant group-by-time interaction (p = 0.895), suggesting that comorbid PTSD did not impact the antidepressant effectiveness of ketamine. Significant improvements in PTSD symptoms were observed in overall PCL-5 scores, t(66) = 6.66, p < 0.001, and across all PCL-5 symptom clusters with moderate to large effect sizes. In a real-world sample of TRD patients, ketamine was effective in reducing symptoms of depression and PTSD, regardless of PTSD comorbidity. These findings highlight ketamine's potential as a novel intervention for a patient population that is frequently non-responders to conventional treatments. Future randomized controlled trials should explore mediating factors of improvement and long-term effects.</p>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"69-77"},"PeriodicalIF":6.1,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dilemmas in psychedelic medicine: From ethics to regulation and equity.","authors":"Albino J Oliveira-Maia, Carolina Seybert","doi":"10.1016/j.euroneuro.2024.11.003","DOIUrl":"https://doi.org/10.1016/j.euroneuro.2024.11.003","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"67-68"},"PeriodicalIF":6.1,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-stratified mortality estimates in people with schizophrenia: A systematic review and meta-analysis of cohort studies of 2,700,825 people with schizophrenia.","authors":"Marco Solmi, Giovanni Croatto, Nicholas Fabiano, Stanley Wong, Arnav Gupta, Michele Fornaro, Lynne Kolton Schneider, S Christy Rohani-Montez, Leanne Fairley, Nathalie Smith, István Bitter, Philip Gorwood, Heidi Taipale, Jari Tiihonen, Samuele Cortese, Elena Dragioti, Ebba Du Rietz, Rene Ernst Nielsen, Joseph Firth, Paolo Fusar-Poli, Catharina Hartman, Richard I G Holt, Anne Høye, Ai Koyanagi, Henrik Larsson, Kelli Lehto, Peter Lindgren, Mirko Manchia, Merete Nordentoft, Karolina Skonieczna-Żydecka, Brendon Stubbs, Davy Vancampfort, Eduard Vieta, Michele De Prisco, Laurent Boyer, Mikkel Højlund, Christoph U Correll","doi":"10.1016/j.euroneuro.2024.11.001","DOIUrl":"https://doi.org/10.1016/j.euroneuro.2024.11.001","url":null,"abstract":"<p><p>The differential influence of sex on premature mortality in schizophrenia is unclear. This study assessed the differences in all-cause and specific cause mortality risks in people with schizophrenia compared to several control groups stratified by sex. We conducted a PRISMA 2020-compliant systematic review and random-effects meta-analysis of cohort studies assessing mortality relative risk (RR) for people with schizophrenia, comparing by sex. We measured publication bias and conducted a quality assessment through the Newcastle-Ottawa scale. We meta-analyzed 43 studies reporting on 2,700,825 people with schizophrenia. Both males and females with schizophrenia had increased all-cause mortality vs. comparison groups (males, RR=2.62, 95%CI 2.35-2.92; females, RR=2.56, 95%CI 2.27-2.87), suicide (males, RR=9.02, 95%CI 5.96-13.67; females, RR=12.09, 95%CI 9.00-16.25), and natural cause mortality (males, RR=2.11, 95%CI 1.88-2.38; females, RR=2.14, 95%CI 1.93-2.38). No statistically significant differences in sex-dependent mortality risk emerged. There was an age-group-dependent increased mortality risk in females < 40 years vs. >/=40 years old (RR=4.23/2.17), and significantly higher risk of death due to neurological disorders (dementia) in males vs. females (RR=5.19/2.40). Increased mortality risks were often associated with specific modifiable risk factors. The increased mortality risk did not improve over time, calling for more studies to identify modifiable factors, and for better physical healthcare for males and females with schizophrenia.</p>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"56-66"},"PeriodicalIF":6.1,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142767569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of mortality and complications in people with depressive disorder and diabetes mellitus: A 20-year population-based propensity score-matched cohort study","authors":"Matthew Tsz Ho Ho ,&nbsp;Joe Kwun Nam Chan ,&nbsp;Heidi Ka Ying Lo ,&nbsp;Catherine Zhiqian Fang ,&nbsp;Corine Sau Man Wong ,&nbsp;Krystal Chi Kei Lee ,&nbsp;Francisco Tsz Tsun Lai ,&nbsp;Amy Pui Pui Ng ,&nbsp;Ken Qingqi Chen ,&nbsp;William Chi Wai Wong ,&nbsp;Wing Chung Chang","doi":"10.1016/j.euroneuro.2024.11.011","DOIUrl":"10.1016/j.euroneuro.2024.11.011","url":null,"abstract":"<div><div>People with depression have increased premature mortality and elevated prevalence of diabetes-mellitus compared to general population. However, risk of mortality and diabetes-related complications among patients with depression and co-occurring diabetes is under-studied. This population-based propensity score-matched (1:10) cohort study identified 12,175 patients with pre-existing depression and incident-diabetes (depression-diabetes group) and 117,958 patients with incident-diabetes only (diabetes-only group) between 2002 and 2021 in Hong-Kong, using territory-wide medical-record database of public-healthcare services, to investigate whether depression increased the risk of overall mortality, complications and post-complication mortality in people with diabetes. Associations of depression with all-cause mortality, complication and post-complication all-cause mortality rates were examined by Cox proportional-hazards model. Complications were assessed by Diabetes-Complications-Severity-Index (DCSI). Associations of complications, in terms of DCSI scores (complication burden), specific types and two-way combinations of complications (complication patterns) with all-cause mortality rate in depression were also examined. Our results showed that depression-diabetes group exhibited increased all-cause mortality risk (adjusted hazards-ratio: 1.06 [95 %CI: 1.02–1.10]) relative to diabetes-only group, particularly among men and older age group, with significantly higher rate of experiencing neuropathy (1.44 [1.27–1.62]) and metabolic complications (1.30 [1.09–1.56]) and lower likelihood of peripheral-vascular complications, retinopathy and nephropathy, albeit comparable macrovascular and microvascular complication rates. The mortality-rate-ratio for patients with depression and diabetes was significantly higher than patients with diabetes-only at a low level of complication burden. In conclusion, depression patients with co-occurring diabetes are at increased risk of excess mortality. Further research is warranted to improve diabetes-related outcomes and reduce mortality gap in this vulnerable population.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"92 ","pages":"Pages 10-18"},"PeriodicalIF":6.1,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142745072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amphiphysin and GAD65 IgG antibodies in patients with obsessive-compulsive syndromes","authors":"Katharina von Zedtwitz ,&nbsp;Bernd Feige ,&nbsp;Alexander Maier ,&nbsp;Sarah L. Schaefer ,&nbsp;Kathrin Nickel ,&nbsp;Marco Reisert ,&nbsp;Kai Spiegelhalder ,&nbsp;Nils Venhoff ,&nbsp;Joachim Brumberg ,&nbsp;Horst Urbach ,&nbsp;Rick Dersch ,&nbsp;Miriam A. Schiele ,&nbsp;Katharina Domschke ,&nbsp;Ludger Tebartz van Elst ,&nbsp;Volker A. Coenen ,&nbsp;Luciana Hannibal ,&nbsp;Harald Prüss ,&nbsp;Simon J. Maier ,&nbsp;Dominique Endres","doi":"10.1016/j.euroneuro.2024.10.005","DOIUrl":"10.1016/j.euroneuro.2024.10.005","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"90 ","pages":"Pages 80-82"},"PeriodicalIF":6.1,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142748721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between genetic risk of attention deficit hyperactivity disorder and trajectories of daily gaming time in children","authors":"Nagahide Takahashi ,&nbsp;Akemi Okumura ,&nbsp;Tomoko Nishimura ,&nbsp;Taeko Harada ,&nbsp;Toshiki Iwabuchi ,&nbsp;Md Shafiur Rahman ,&nbsp;Kenji J. Tsuchiya","doi":"10.1016/j.euroneuro.2024.11.012","DOIUrl":"10.1016/j.euroneuro.2024.11.012","url":null,"abstract":"","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 54-55"},"PeriodicalIF":6.1,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142746278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of mortality and complications in patients with severe mental illness and co-occurring diabetes mellitus: A systematic review and meta-analysis","authors":"Matthew Tsz Ho Ho ,&nbsp;Joe Kwun Nam Chan ,&nbsp;Will Chi Yuen Chiu ,&nbsp;Lucy Lo Wah Tsang ,&nbsp;Kenneth Shut Wah Chan ,&nbsp;Mimi Mei Cheung Wong ,&nbsp;Ho Hon Wong ,&nbsp;Pui Fai Pang ,&nbsp;Wing Chung Chang","doi":"10.1016/j.euroneuro.2024.11.002","DOIUrl":"10.1016/j.euroneuro.2024.11.002","url":null,"abstract":"<div><div>People with severe-mental-illness (SMI), often defined as “schizophrenia-spectrum disorders and bipolar disorder”, have increased premature mortality and elevated prevalence of diabetes compared with general population. Evidence indicated that one-third of their premature death was from cardiovascular diseases (CVD), with risk conferred by diabetes. Although earlier studies have examined SMI-associated diabetes-related outcomes, findings were inconsistent and not systematically evaluated. We systematically reviewed and quantitatively synthesized diabetes-related outcomes in patients with SMI (schizophrenia-spectrum disorders and bipolar disorder) by searching Embase, MEDLINE, PsycInfo, and Web-of-Science from inception to 31-March-2024, and included studies examining mortality and complication outcomes in SMI patients with co-occurring diabetes relative to patients with diabetes-only. Results were synthesized by random-effects models, with stratified-analyses by study-level characteristics. The study was registered with PROSPERO (CRD42023448490). Twenty-one studies involving 161,156 SMI patients with co-occurring diabetes were identified from ten regions. Regarding mortality risk, SMI-diabetes group exhibited increased risks of all-cause mortality (RR=1.77[95 % CI: 1.46–2.14]) and CVD-specific mortality (1.88[1.73–2.04]) relative to diabetes-only group. All-cause mortality risk was present in distinct regions and has persisted over time. Regarding complication risk, SMI-diabetes group showed higher risk of any complications (1.23[1.06–1.43]) than comparison, with stratified-analyses showing higher risk of metabolic-complications (1.84[1.58–2.15]), and lower likelihood of peripheral-vascular complications (0.91[0.84–0.99]), neuropathy (0.85[0.78–0.93]), and retinopathy (0.70[0.60–0.82]), albeit comparable cardiovascular-complications (1.04[0.89–1.22]), cerebrovascular-complications (1.07[0.86–1.33]), and nephropathy (0.92[0.72–1.17]). High heterogeneity was noted and could not be fully-explained by subgroup-analyses. Implementation of targeted interventions is needed to rectify their diabetes-related outcomes and mortality gap.</div></div>","PeriodicalId":12049,"journal":{"name":"European Neuropsychopharmacology","volume":"91 ","pages":"Pages 25-36"},"PeriodicalIF":6.1,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142722854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}